Lopes RD, et al. - Via a network meta-analysis of randomized controlled trials including over 10,000 participants, researchers analyzed the safety and effectiveness of various antithrombotic regimens. Women were 20%-29% of the trial population; the mean age varied from 70 to 72 years, and most had high risk of thromboembolic and bleeding events. An association between non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) plus P2Y₁₂ inhibitor regimen with less bleeding was found vs VKAs plus dual antiplatelet therapy (DAPT). Reduced bleeding, including intracranial bleeding, was achieved through strategies that omitted aspirin, with no significant difference in major adverse cardiovascular events, vs strategies that involved aspirin. NOAC plus P2Y₁₂ inhibitor as the optimal regimen post-percutaneous coronary intervention for high-risk patients with atrial fibrillation was suggested. Also, avoiding a regimen of VKA plus DAPT should be considered.